Navigation Links
Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
Date:2/24/2009

LONDON, February 24 /PRNewswire/ --

- Syndicate Comprises Leading Sector Investors Clarus Ventures, MVM Life Science Partners and Novartis Option Fund

Heptares Therapeutics Ltd, the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), announces today it has raised GBP21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip international venture capital firms. Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science Partners, and the Novartis Option Fund. All three investors contributed equally.

Michael Steinmetz for Clarus Ventures and Anja Koenig for the Novartis Option Fund have joined the Heptares Board of Directors as non-executive directors.

Over the next three years, Heptares intends to use the new funds to develop its own pipeline of small-molecule drug candidates using its proprietary StaR(TM) technology platform. These novel drug candidates will be developed against currently intractable GPCRs that are highly validated targets for the treatment of disease. Further progress in the application of StaR technology over this period is also expected to yield commercial partnering opportunities outside Heptares' core focus, for example, improved therapeutic antibodies against GPCRs.

GPCRs play a crucial role in many diseases and are the site of action of 25-30% of current drugs; as such they represent a major area of interest for pharmaceutical companies. However, these membrane proteins are notoriously difficult to isolate from cells in an intact and active form and this has severely restricted efforts to study GPCRs using modern drug discovery techniques.

Heptares' StaR (Stabilised Receptor) technology platform enables the Company to overcome this technology hurdle by engineering and purifying GPCRs in stable and functional conformat
'/>"/>

SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Northwest Biotherapeutics Secures $700,000 Equity Financing
3. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
4. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
5. Pharmacyclics Secures $5.0 Million in Debt Financing
6. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Queens secures £25M for UKs cyber safety
9. Queens secures £25m for UKs cyber-safety
10. Northwest Secures US$1.65 Million Debt Financing
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... testing solutions for the detection of foodborne pathogens, today announced ... Piper Jaffray  26 th Annual Healthcare Conference on December ... at The New York Palace in New York, ... information concerning the Company, its operations, strategies and prospects may ...
(Date:11/24/2014)... November 24, 2014   ... ScienceDirect   Elsevier , a world-leading provider ... pleased to announce the launch of the latest title in ... Current Opinion in Food Science . ... specialists with a new platform to keep up-to-date with the ...
(Date:11/24/2014)... November 24, 2014 The new ... from METTLER TOLEDO demonstrates how to reduce the ... analytics and sample panel design can be complicated, ... and protect against corrosion and deposition. Dedicated single ... significant amount of panel space. Additionally, installing and ...
(Date:11/22/2014)... Richmond, VA (PRWEB) November 21, 2014 ... businessman who understood the need to surround himself with ... visionary, CEO and entrepreneur, his friends often marveled at ... how he lived his life and -- even with ... cure for the Alzheimer’s disease that would ultimately take ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... be outraged at getting a second-rate solution for something as ... consumers demand in almost every other product and service arena. ... products and services as the general metric for assessing whether ... , , Speed is good , ,To paraphrase ...
... Ruling that two Google products do not infringe ... has granted a motion to dismiss a lawsuit brought against ... Shabaz has ruled that Google's AdSense and AutoLink ... Madison-based HyperPhrase Technologies, LLC and its subsidiary, HyperPhrase, Inc. The ...
... nation's top 25 banks have joined an electronic check-clearing network ... unit of Metavante Corp ., the technology subsidiary of ... nation's largest banks now will be able to electronically exchange ... a capability that was encouraged by the federal government following ...
Cached Biology Technology:Damn the incumbents, and full speed ahead 2Damn the incumbents, and full speed ahead 3Damn the incumbents, and full speed ahead 4Wisconsin judge dismisses patent suit vs. Google 2
(Date:11/4/2014)... examining only marketing directed at children on the ... found that the majority of black, middle-income and ... tactics. , Authored by Arizona State University researcher ... the first to examine the use of child-directed ... food restaurants and its relationship to demographics. It ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... research points to a genetic route to understanding and treating ... Penn State University, has identified an ancient gene family that ... the brain. "In healthy people, nerves do not fire ... us to focus on what really matters. Nerve cells ...
... culturing adult human stem cells on a new type of ... about how the cells would differentiate, or what type of ... Aug. 1 edition of Nature Methods . Differentiation ... of cells. Understanding it is key to developing future stem ...
... in Melbourne, Australia, have made a discovery that has ... role in tumour formation. Programmed cell death, also ... as it removes unwanted and damaged cells from our ... autoimmune disease. The research team,s discovery, led ...
Cached Biology News:Epileptic seizures may be linked to an ancient gene family 2New insights into how stem cells determine what tissue to become 2Missing Puma reveals cancer conundrum 2Missing Puma reveals cancer conundrum 3